Partnership
Terra Quantum is a computational drug discovery partner supporting pharmaceutical and biotech companies in the design of novel therapeutics for challenging targets and next-generation modalities.
Author
Sandra von Meier
Head of Business Development Life Science
Terra Quantum AG
Munich, Germany
Sandra is Head BD Life Science at Terra Quantum in 2026. Terra Quantum chemistry unit applies physics driven AI to handle so far too complex modalities through its higher compute power which is faster and more accurate than standard AI.
My organisation
At Terra Quantum AG, we are pioneers in the field of quantum computing, dedicated to harnessing the power of quantum technology to solve some of the world's most complex problems. Our team of experts leverages cutting-edge research and innovative solutions to drive advancements in various industries, from finance to pharmaceuticals. We believe in fostering collaboration and building partnerships that push the boundaries of what is possible with quantum computing. Together, we are shaping the future of technology and delivering transformative solutions that create real value for businesses globally.
About me
BIO – Sandra von Meier (2026)
Sandra von Meier currently leads Business Development for Life Sciences at Terra Quantum, an innovative AI-driven company focused on drug discovery.
Previously, she served as Head of Business Development and Project Management at Desitin, a neurology and rare disease company, where she was responsible for all business development deals and cross-functional projects across the organization.
Before joining Desitin, Sandra was Head of Business Development and Licensing at Debiopharm, overseeing all in-licensing and out-licensing activities. During her tenure, she led several high-profile transactions, including the in-licensing of a USP inhibitor from Novo Nordisk/Forma, a multi-asset partnership with SunRock and Genome to develop novel antibody–drug conjugates (ADCs) for Debiopharm’s oncology pipeline, as well as clinical collaborations with Repare and Gilead. Her most recent public transaction at Debiopharm was the out-licensing of a radiopharmaceutical asset to ITM.
Prior to Debiopharm, Sandra was Senior Director Business Development & Licensing at Bayer, where she was responsible for oncology asset search, evaluation, and transactions, including the M&A transaction with Vividion Therapeutics. Before that, as Director Business Development Oncology at Merck KGaA, she led numerous strategic transactions, including the collaboration on Xevinapant, partnerships with F-star (bispecific antibodies), Vertex (DDR portfolio), and Pfizer for Bavencio (avelumab).
Sandra began her career at Medigene, a publicly listed German biotechnology company, where she closed several transactions, including the commercialization agreement with Astellas for Eligard.
Marketplace (2)
Expertise
Our approach combines first-principles quantum chemistry with tensor-network optimisation algorithms to model protein–ligand interactions with high accuracy, without dependence on large training datasets.
Author